Exploring new compounds that fight breast cancer
Official title: Characterization of novel pyrazole compounds with potent anti-cancer activity
Funded at University of Texas El Paso · NIH-11057589 · Data updated 2026-11-12
This study is looking at new medicines made from pyrazole to see if they can help treat Triple Negative Breast Cancer, which is a tough type of breast cancer, and aims to find better options for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas El Paso NIH-funded |
| Lab location | 1 site (El Paso, United States) |
| Project start | May 1, 2023 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $151,360 |
| NIH project number | 5R16GM149379-03 |
| Project ID | NIH-11057589 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Triple Negative Breast Cancer who have limited treatment options.
✕Less likely to help
Patients with other types of breast cancer or those who are not diagnosed with cancer may not benefit from this research.
What this research studies
This research investigates the effectiveness of novel pyrazole compounds in treating Triple Negative Breast Cancer (TNBC), a particularly aggressive form of breast cancer. The team has screened thousands of compounds to identify those that can effectively kill cancer cells. Using advanced live-cell imaging techniques, they have found several promising candidates that induce cancer cell death through specific biological mechanisms. The goal is to understand how these compounds work and to develop new treatment options for patients with TNBC.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for patients suffering from Triple Negative Breast Cancer.
How similar studies have gone: Previous research has shown promise in using novel compounds to target aggressive cancer types, suggesting potential success for this approach.
Where this research is happening
-
University of Texas El Paso
El Paso, United States Active
Researchers
- Principal investigator: Aguilera, Renato J — University of Texas El Paso
- Study coordinator: Aguilera, Renato J
Related research
Other NIH-funded projects on the same topics.
-
Targeting AR-driven enhancer condensates to overcome antiandrogen resistance in prostate cancer
A patient-facing overview of a project that may help men with prostate cancer become more responsive to antiandrogen treatments.
-
Adapted DSMES Digital Health for Mexican-origin Hispanics with Type 2 Diabetes
A digital health program adapted from an in-person diabetes education approach is designed to help Mexican-origin adults with type 2 diabetes improve self-management and access to care.
-
Targeting the adenosine pathway to boost immune responses against liver cancer
Aimed at helping people with hepatocellular carcinoma, this grant explores a drug target in the tumor environment to make immunotherapies work better.
-
Recruitment Core for Hispanic Health Disparities researchers
A grant to recruit and keep leading experts in Hispanic health issues at a Texas university to strengthen research and collaboration.
-
Community Engagement Core for Border Biomedical Research Center
A community-focused center at UTEP partners with local residents to help recruit, keep, and share findings from health research that affects the Borderplex region.
-
Mentorship and Career Development Core to Help Researchers Grow
This grant supports a mentorship program at a university to help senior postdocs and early-stage investigators build careers, develop professional skills, and prepare competitive grant proposals.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.